Tissue transglutaminase expression and drug resistance in ovarian cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer Statistics. CA Cancer J. Clin.57, 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Mcguire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl J. Med.334, 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Yamada KM, Miyamoto S. Integrin transmembrane signaling and cytoskelatal control. Curr. Opin. Cell Biol.7, 681–689 (1995).
   PubMed Web of Science ®Google Scholar
• Ricciardelli C, Rodgers RJ. Extracellular matrix of ovarian tumors. Sem. Reproduc. Med.24, 270–282 (2006).
   PubMed Web of Science ®Google Scholar
• Verma A, Mehta K. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist. Update10, 144–151 (2007).
   PubMed Web of Science ®Google Scholar
• Mangala SL, Gillogli M, Sahin S, Arun B, Mehta K. Tissue transglutaminase-mediated alterations in extracellular matrix inhibit invasion. Mol. Cancer4, 1–8 (2005).
   PubMed Web of Science ®Google Scholar
• Hwang JH, Mangala LS, Fok JY et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res.68, 5849–5858 (2008).
   PubMed Web of Science ®Google Scholar
• Fok JY, Ekmekcioglu S, Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol. Cancer Ther.5, 1493–1503 (2006).
   PubMed Web of Science ®Google Scholar
• Herman JF, Mehta K. Implications of increased tissue transglutaminase expression in drug-resistant breast cancer (MCF-7) cells. Oncogene25, 3049–3058 (2006).
   PubMed Web of Science ®Google Scholar
• Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene26, 2450–2470 (2007).
   Google Scholar
• Akimov SS, Krylov D, Fleishmann LF, Belkin AM. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J. Cell Biol.148, 825–838 (2000).
   PubMed Web of Science ®Google Scholar
• Satpathy M, Cao L, Pincheira R et al. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res.67, 7194–7202 (2007).
   PubMed Web of Science ®Google Scholar
• Lorand L, Graham R. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Mol. Cell Biol.4, 140–156 (2003).
   PubMed Web of Science ®Google Scholar
• Mehta K. Transglutaminases: family of enzymes with diverse functions. Prog. Exp. Tumor Res.38, 1–18 (2005).
   PubMed Web of Science ®Google Scholar
• Begg GE, Holman SR, Stokes PH et al. Mutation of a critical GTP-binding arginine in transglutaminase 2 disinhibits intracellular crosslinking activity. J. Biol. Chem.281, 12603–12609 (2006).
   PubMed Web of Science ®Google Scholar
• Verderio EAM, Johnson TS, Griffin M. Transglutaminases in wound healing and inflammation. Prog. Exp. Tumor Res.38, 89–114 (2005).
   PubMed Web of Science ®Google Scholar
• Ballestar E, Boix-Chornet M, Franco L. Conformational changes in the nucleosome followed by the selective accessibility of histone glutamines in the transglutaminase reaction; effect of salt concentrations. Biochemistry40, 1922–1929 (2001).
   PubMed Web of Science ®Google Scholar
• Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM. Targeted inactivation of Gh/tissue transglutaminase II. J. Biol. Chem.276, 20673–20678 (2001).
   PubMed Web of Science ®Google Scholar
• Verma A, Wang H, Manavathi B et al. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res.66, 10525–10533 (2006).
   PubMed Web of Science ®Google Scholar
• Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin. Cancer Res.10, 8068–8076 (2004).
   PubMed Web of Science ®Google Scholar
• Yuan L, Siegel M, Choi K et al. Transglutaminase 2 inhibitor, KCC009 disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene26, 2563–2573 (2006).
   PubMed Web of Science ®Google Scholar
• Akar A, Ozpolat B, Mehta K, Fok JY, Kondo Y, Lopez-Berestein G. Tissue transglutaminase (TG2) expression protects pancreatic cancer cells from autophagy. Mol. Cancer Res.5, 241–249 (2007).
   PubMed Web of Science ®Google Scholar
• Kim DS, Park SS, Nam BH, Kim IH, Kim SY. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-κB inactivation. Cancer Res.66, 10936–10943 (2006).
   PubMed Web of Science ®Google Scholar
• Cao L, Petrusca DN, Satpathy M et al. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin induced apoptosis by promoting cell survival signaling. Carcinogenesis29, 1893–1900 (2008).
   PubMed Web of Science ®Google Scholar
• Verma A, Mehta K. Tissue transglutaminase-mediated activation of nuclear transcription factor-κB as a target for cancer treatment. Curr. Cancer Drug Targets7, 559–565 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang WG, Ablin R, Douglas-Jones A, Mansel RE. Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol. Rep.10, 2039–2044 (2003).
   PubMed Web of Science ®Google Scholar
• Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res.63, 8614–8622 (2003).
   PubMed Web of Science ®Google Scholar
• Antonyak MA, Miller AM, Jansen JM et al. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J. Biol. Chem.279, 41461–41467 (2004).
   PubMed Web of Science ®Google Scholar
• Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase and inhibits melanoma tumor growth and metastasis. Proc. Natl Acad. Sci. USA103, 9023–9028 (2006).
   PubMed Web of Science ®Google Scholar
• Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin. Exp. Metastasis20, 203–213 (2003).
   PubMed Web of Science ®Google Scholar
• Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol.11, 130–135 (2001).
   PubMed Web of Science ®Google Scholar
• Kotsakis P, Griffin M. Tissue transglutaminase in tumour progression: friend or foe? Amino Acids33, 373–384 (2007).
   PubMed Web of Science ®Google Scholar
• McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal adhesion kinase in cancer – a new therapeutic opportunity. Nat. Rev. Cancer5, 505–515 (2005).
   PubMed Web of Science ®Google Scholar
• Verma A, Koul D, Guha S, Wang H, Mehta K. Transglutaminase-mediated regulation of PTEN in pancreatic cancer cells. Clin. Cancer Res.14, 1997–2005 (2008).
   PubMed Web of Science ®Google Scholar
• Wang X, Trotman LC, Koppie T et al. NEDD4–1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell128, 129–139 (2007).
   PubMed Web of Science ®Google Scholar
• Karin M, Cao Y, Greten F, Li Z. NF-kB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer2, 301–310 (2002).
   PubMed Web of Science ®Google Scholar
• Mann AS, Verma A, Wang H et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-κB in cancer cells: delineation of a novel pathway. Cancer Res.66, 8788–8795 (2006).
   PubMed Web of Science ®Google Scholar
• Verma A, Guha S, Diagaradjane P et al. Tissue transglutaminase as a therapeutic target for inhibiting growth and metastasis of pancreatic ductal adenocarcinoma. Clin. Cancer Res.14, 2476–2483 (2008).
   PubMed Web of Science ®Google Scholar